<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective AnalysisJustin F. Gainor, Mari Mino–Kenudson, Tiffany G. Huynh et al.|Clinical Cancer Research|2016Cited by 1.2k
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade TherapyChristina Pfirschke, Mikaël J. Pittet, Camilla Engblom et al.|Immunity|2016Cited by 954
Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune MicroenvironmentTiffany G. Huynh, Mari Mino–Kenudson|Journal of Thoracic Oncology|2016Cited by 88